BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · IEX Real-Time Price · USD
1.120
-0.050 (-4.27%)
Jul 2, 2024, 4:00 PM EDT - Market closed
BioXcel Therapeutics Revenue
BioXcel Therapeutics had revenue of $1.76M in the twelve months ending March 31, 2024, with 202.24% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $582.00K with 182.52% year-over-year growth. In the year 2023, BioXcel Therapeutics had annual revenue of $1.38M with 268.00% growth.
Revenue (ttm)
$1.76M
Revenue Growth
+202.24%
P/S Ratio
23.94
Revenue / Employee
$23,730
Employees
74
Market Cap
42.03M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.38M | 1.01M | 268.00% |
Dec 31, 2022 | 375.00K | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Allurion Technologies | 48.78M |
Bionano Genomics | 37.47M |
LAVA Therapeutics | 13.63M |
Mobile-health Network Solutions | 7.87M |
Marker Therapeutics | 3.32M |
BTAI News
- 5 weeks ago - BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting - GlobeNewsWire
- 7 weeks ago - BioXcel Therapeutics Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024 - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia - GlobeNewsWire
- 3 months ago - BioXcel Therapeutics Announces $25 Million Registered Direct Offering - GlobeNewsWire